AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally.
The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors.
It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits.
In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency.
Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names.
It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships.
The company was founded in 1988 and is headquartered in Latham, New York.
Country | United States |
IPO Date | Jun 1, 2004 |
Industry | Medical - Instruments & Supplies |
Sector | Healthcare |
Employees | 748 |
CEO | James C. Clemmer |
Contact Details
Address: 14 Plaza Drive Latham, New York United States | |
Website | https://www.angiodynamics.com |
Stock Details
Ticker Symbol | ANGO |
Exchange | NASDAQ |
Fiscal Year | June - May |
Reporting Currency | USD |
CIK Code | 0001275187 |
CUSIP Number | 03475V101 |
ISIN Number | US03475V1017 |
Employer ID | 11-3146460 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
James C. Clemmer | Chief Executive Officer, President & Director |
Stephen A. Trowbridge | Executive Vice President & Chief Financial Officer |
Benjamin H. Davis | Senior Vice President of Business Development & Strategy |
Chad T. Campbell | Senior Vice President and GM of Global Vascular Access & Oncology Business Unit |
Juan Carlos Serna | Senior Vice President of Scientific & Clinical Affairs |
Kim L. Seabury | Senior Vice President of Information Technology |
Laura Piccinini | Senior Vice President & GM of Endovascular Therapies and International |
Marna I. Bronfen-Moore | Senior Vice President of Human Resources |
Saleem M. Cheeks | Vice President of Communications |
Warren G. Nighan | Senior Vice President of Regulatory Affairs, Quality & Global Supply Chain |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 04, 2024 | 4 | Filing |
Dec 04, 2024 | 3 | Filing |
Nov 15, 2024 | 8-K | Current Report |
Nov 08, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Oct 23, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Oct 10, 2024 | 4 | Filing |
Oct 08, 2024 | 4 | Filing |
Oct 08, 2024 | 4 | Filing |
Oct 03, 2024 | 10-Q | Quarterly Report |
Oct 03, 2024 | 8-K | Current Report |